Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SURFACE LOGIX, INC.

Home Clinical Trial Sponsors and OrganizationsSURFACE LOGIX, INC.

SURFACE LOGIX, INC.

CLOSED

50 Soldiers Field Pl, Brighton, Massachusetts, United StatesPrivate

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1

33.3%

Trial Status Distribution

Active, not recruiting

3

100.0%

Clinical Trials

Trials sponsored by this organization (3)

A pilot Phase IIa, randomised, double blind, placebocontrolled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5 mg or 10 mg once daily for up to 14 days in patients with hypertension.

Active, not recruiting

Aug 200740 participants

A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days in patients with secondary Raynaud’s disease.

Active, not recruiting

A pilot Phase IIa randomised, double blind, placebo-controlled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5, 10 or 20 mg once daily for up to 14 days in patients with hypertension.

Active, not recruiting

Jan 200720 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals
News

Back to Organizations